Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Still Most Predictable Part of Drug Development, Despite Bumps, Woodcock Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Janet Woodcock may take a lot of criticism over problems with FDA’s drug application review and approval process, but she maintains sponsor success at gaining agency approval is better than any other portion of the development process.
Advertisement

Related Content

Blame The Science, Not Regulation, For Targeted Therapy Shortfalls – FDA
NDA, BLA Submissions Expected To Fall Again in FY 2011
FDA Sets A Fast Pace Of Novel Approvals In First Half, But That's Likely To Slow
Cardio Safety: Does FDA Expect More From Obesity Than Diabetes Products?
Want A Predicable Review For Your NDA? Use eCTD And Don't Amend It
Want A Predicable Review For Your NDA? Use eCTD And Don't Amend It
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees
Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees
The Politics Of Avandia: CDER Memos Reveal Frustration With External Pressure

Topics

Advertisement
UsernamePublicRestriction

Register

PS004754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel